¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѺñ´¢±â°úÇÐȸ 2018 KPS-APSU Joint International Symposium : 2018-08-31

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѺñ´¢±â°úÇÐȸ 2018 KPS-APSU Joint International Symposium : 2018-08-31
±³À°ÀÏÀÚ : 2018-08-31
±³À°Àå¼Ò : ¼­¿ï¼º¸ðº´¿ø ¸¶¸®¾ÆȦ  
±³À°ÁÖÁ¦ : 2018 KPS-APSU Joint International Symposium      
ÁÖÃÖ±â°ü : ´ëÇѺñ´¢±â°úÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑÀü¸³¼±ÇÐȸ  
´ã´çÀÚ : È«¼º±Ô
¿¬¶ôó : 02-556-7473  
À̸ÞÀÏ : soyeon@iztec.co.kr      
±³À°Á¾·ù ; ºñ´¢±â°ú      
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 4Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 4 ½Ã°£ 0ºÐ  
¼¼ºÎ¼ö°­·á : 150,000¿ø      
ºñ°í »çÀüµî·Ï (6/1~8/20) ÀÇ»ç 10¸¸¿ø / °£È£»ç ±× ¿Ü 7¸¸¿ø ÇöÀåµî·Ï (8/31~9/1) ÀÇ»ç 15¸¸¿ø / °£È£»ç ±× ¿Ü 7¸¸¿ø      
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 08¿ù 31ÀÏ ¸¶¸®¾ÆȦ 13:10~13:30 Current status of PSA screening in USA and its influence to outcome of the prostate cancer treatment  Peter Carroll (USA)(UCSF, USA) 
±³À°½Ã°£ 08¿ù 31ÀÏ ¸¶¸®¾ÆȦ 13:30~13:50 Strengths and limitations of MRI for interrogation of the prostate  Robert Reiter (USA)(UCLA, USA) 
±³À°½Ã°£ 08¿ù 31ÀÏ ¸¶¸®¾ÆȦ 13:50~14:10 Genomic tests for prostate cancer  Stephen J. Freedland (USA)(Cedars-Sinai, USA) 
±³À°½Ã°£ 08¿ù 31ÀÏ ¸¶¸®¾ÆȦ 14:10~14:30 Radical prostatectomy in North America: current trends and future direction  Matthew Cooperberg (USA)(UCSF, USA) 
±³À°½Ã°£ 08¿ù 31ÀÏ ¸¶¸®¾ÆȦ 14:30~14:50 Panel Discussion  Àü¼º¼öHong Gee SimÈ«ÁØÇõBannakij Lojanapiwat¹®È«»óGiuseppe ProcopioÈ«¼º±ÔShigeo HorieÇÑ¿õ±Ô(»ï¼º¼­¿ïº´¿øSingapore General Hospital¼­¿ï¾Æ»êº´¿øFaculty of Medicine, Chiang Mai University, Chiang Mai, ThailandÇѾç´ëÇб³ ±¸¸®º´¿øFondazione Istituto Nazionale Tumori, Milan, ItalyºÐ´ç¼­¿ï´ëÇб³º´¿øGraduate School of Medicine, Juntendo University, Tokyo, Japan¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 08¿ù 31ÀÏ ¸¶¸®¾ÆȦ 14:50~15:10 The role of peri-operative systemic therapy in Renal Cell Carcinoma  Peter Mulders (Netherlands)(Radboud University Medical Center Nijmegen,The Netherlands) 
±³À°½Ã°£ 08¿ù 31ÀÏ ¸¶¸®¾ÆȦ 15:10~15:25 Biomarkers for optimal patient selection of systemic thereapy in mRCC  ¹ÚÀ翵(°í´ë¾È»êº´¿ø) 
±³À°½Ã°£ 08¿ù 31ÀÏ ¸¶¸®¾ÆȦ 15:25~15:40 Current and future application of Immune check point inhibitors  ±èÀ¯Á¤(ºÐ´ç¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 08¿ù 31ÀÏ ¸¶¸®¾ÆȦ 15:40~15:55 Panel Discussion  Jacob Pang (Taiwan)Àü»óÇöRainy Umbas (Indonesia)¼­¼ºÀÏStephen J. Freedland (USA)À̽ÂÁÖTeng Aik Ong (Malaysia)Àü½ÂÇöPeter Mulders (Netherlands)(President of Taiwan Urological Oncology Association (TUOA)¿ï»ê´ëº´¿øUniversity of Indonesia»ï¼º¼­¿ïº´¿øCedars-Sinai, USA¼ººó¼¾Æ®º´¿øUniversity of Malaysia°æÈñ´ëº´¿øCedars-Sinai, USA) 
±³À°½Ã°£ 08¿ù 31ÀÏ ¸¶¸®¾ÆȦ 16:15~16:35 Clinical applications from TCGA project  Seth Lerner (USA)(Baylor College of Medicine, USA) 
±³À°½Ã°£ 08¿ù 31ÀÏ ¸¶¸®¾ÆȦ 16:35~16:50 The evidence for the extent of lymphadenectomy in bladder urothelial carcinoma  È«¹ü½Ä(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 08¿ù 31ÀÏ ¸¶¸®¾ÆȦ 16:50~17:05 Bladder-sparing in muscle invasive bladder cancer: Selection and optimal treatment  ¿ÀÁ¾Áø(Â÷ÀÇ°úÇдëÇб³) 
±³À°½Ã°£ 08¿ù 31ÀÏ ¸¶¸®¾ÆȦ 17:05~17:20 Neoadjuvant and adjuvant therapy: Current indications, trials, and patient selection  À̵¿Çö(ÀÌÈ­¿©ÀÚ´ëÇб³ ¸ñµ¿º´¿ø) 
±³À°½Ã°£ 08¿ù 31ÀÏ ¸¶¸®¾ÆȦ 17:20~17:30 Panel Discussion  ±è¿øÀçEddie Chan (Hong Kong)Á¶¹®±âRobert Reiter (USA)¹ÚÈ«¼® Hong Gee Sim (Singapore)ÇÑÁØÇöPeter Carroll (USA)Matthew Cooperberg (USA)(ÃæºÏ´ëÇб³º´¿ø¼Ò¼ÓÈ®ÀÎÁßÇѱ¹¿øÀÚ·ÂÀÇÇпøUCLA, USA°í´ë±¸·Îº´¿øSingapore General HospitalÇѸ²´ëÇб³ µ¿Åº¼º½Éº´¿øUCSF, USAUCSF, USA) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѺñ´¢±â°úÇÐȸ 2018 KPS-APSU Joint International Symposium : 2018-08-31""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2018 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ(8¿ù 31ÀÏ) : 2018-08-31
´ÙÀ½±Û ´ëÇѽŻý¾ÆÇÐȸ Á¦9Â÷ ±³À°¼¼¹Ì³ª¥° : 2018-08-31
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
615 ÃæºÏ ´ëÇѽŻý¾ÆÇÐȸ ÃæûÁöȸ Áý´ãȸ : 2018-09-18 0 681 2018-08-29
614 ´ë±¸ ´ë±¸°æºÏ°³¿ø³»°úÀÇ»çȸ ³»½Ã°æÁý´ãȸ : 2018-09-18 0 1,440 2018-08-29
613 ¼­¿ï ÇѸ²´ëÇб³°­µ¿¼º½Éº´¿ø 2018³â 9¿ù ºñ´¢ÀÇÇаú ¿¬¼ö°­Á : 2018-09-18 0 1,570 2018-08-29
612 ÃæºÏ ÃæºÏ´ëÇб³º´¿ø ³ëÀÎÁ¤½ÅÀÇÇÐ : 2018-09-17 0 1,217 2018-08-29
611 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø 2018³â Á¦25Â÷ ½Å°æ°ú ¿¬¼ö°­Á : 2018-09-16 0 853 2018-08-29
610 ´ëÀü ´ëÇÑÁ¤Çü¿Ü°úÃÊÀ½ÆÄÇÐȸ Á¦20Â÷ ±Ù°ñ°Ý°è ÃÊÀ½ÆÄ¿öÅ©¼¥ (Advanced Course-ôÃß) : 2018-09-16 0 1,350 2018-08-29
609 ¼­¿ï ´ëÇÑ°³¿øÀÇÇùÀÇȸ 2018³âµµ 34Â÷ ¼Òû°úÀÇ»çȸ ¿¬¼ö°­Á : 2018-09-16 0 1,162 2018-08-29
608 ´ë±¸ Á¦14ȸ ¼­¿ï¾Æ»êº´¿ø & ´ë±¸ÆÄƼ¸¶º´¿ø °øµ¿ ½ÉÆ÷Áö¾ö : 2018-09-15 0 1,737 2018-08-29
607 °­¿ø 2018³â ´ëÇÑôÃß¿Ü°ú °­¿øÁöȸ Ãß°è½ÉÆ÷Áö¿ò: 2018-09-15 0 463 2018-08-29
606 ¿ï»ê 2018³â Á¦2ȸ ´ëÇѺñ´¢ÅëÇÕÀÇÇבּ¸È¸ ½ÉÆ÷Áö¿ò : 2018-09-15 0 521 2018-08-29
605 ¼­¿ï 2018³â Á¦2ȸ ´ëÇÑÇÙÀÇÇÐȸ ÇÙÀÇÇÐ Á¤µµ°ü¸® ½ÉÆ÷Áö¿ò : 2018-09-15 0 716 2018-08-29
604 ¿ï»ê ¿ï»ê´ëÇб³º´¿ø 2018³â ´ëÇѼҾƺñ´¢±â°úÇÐȸ Ãß°èÇмú´ëȸ(Áõ·ÊÅä·Ðȸ) : 2018-09-15 0 706 2018-08-29
603 ´ë±¸ Á¦4ȸ °æºÏ´ëÇб³¾î¸°À̺´¿ø ½ÉÆ÷Áö¾ö : 2018-09-15 0 760 2018-08-29
602 ¼­¿ï 2018³â ´ëÇÑÀÓ»óÅëÁõÇÐȸ Ãß°èÇмú´ëȸ ¿öÅ©¼ó : 2018-09-15 0 1,231 2018-08-29
601 ¼­¿ï 2018³â ´ëÇÑÀÓ»óÅëÁõÇÐȸ Ãß°èÇмú´ëȸ ¿¬¼ö°­Á : 2018-09-15 0 946 2018-08-29
1361 | 1362 | 1363 | 1364 | 1365 | 1366 | 1367 | 1368 | 1369 | 1370
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷